Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
For Immediate Release
Chicago, IL – March 5, 2024 – Stocks in this week’s article are Protagonist Therapeutics PTGX, AxoGen AXGN, Western Digital WDC and Phunware PHUN.
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Companies displaying incessant earnings growth will continue to captivate almost everyone in the investment world, from top brass to research analysts. This is because earnings are a measure of the money a company is making. Still, earnings acceleration works better when lifting the stock price.
Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in the stock price. Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics, AxoGen, Western Digital and Phunware.
Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-over-quarter earnings growth increases within a stipulated time frame, it can be called earnings acceleration.
In the case of earnings growth, you pay for something that is already reflected in the stock price. But earnings acceleration helps spot stocks that haven’t yet caught the attention of investors. Once secured, it will invariably lead to a rally in the share price. This is because earnings acceleration considers both the direction and magnitude of growth rates.
An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may sometimes drag prices down.
The above criteria narrowed the universe of around 7,735 stocks to only four. Here are the stocks:
Protagonist Therapeutics is a clinical-stage biopharmaceutical company. It currently has a Zacks Rank #2 (Buy). PTGX’s expected earnings growth rate for the current year is 180.6%. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
AxoGen engages in developing and marketing surgical solutions for peripheral nerves. The company currently has a Zacks Rank #2. AXGN’s expected earnings growth rate for the current year is 46.7%.
Western Digital is a leading developer and manufacturer of data storage devices and solutions based on NAND flash and hard disk drive technologies. The company currently has a Zacks Rank #2. WDC’s expected earnings growth rate for the current year is 47.6%.
Phunware provides a cloud platform for mobile. The company currently has a Zacks Rank #2. PHUN’s expected earnings growth rate for the current year is 39.9%.
You can sign up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2235092/4-must-buy-stocks-for-remarkable-earnings-acceleration
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Western Digital Corporation (WDC) : Free Stock Analysis Report
AxoGen, Inc. (AXGN) : Free Stock Analysis Report
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
Phunware (PHUN) : Free Stock Analysis Report
